Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 9/20 | 0.58 |
| ▸ | MIF | P14174 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091430 | 0.87 | MIF (0.58) | GPR35MIFCA9MEN1GLA | |
| SCHEMBL622794 | 0.77 | KDM4E (0.64) | GPR35MIFCA9MEN1GLA | |
| SCHEMBL1091047 | 0.76 | CA12 (0.37) | GPR35CA9MEN1KMT2AKDM4E | |
| SCHEMBL1091133 | 0.76 | MAOB (0.56) | GPR35MIFCA9KMT2AKDM4E | |
| SCHEMBL15515840 | 0.75 | CYP2A6 (0.58) | GPR35 | |
| SCHEMBL15842406 | 0.74 | GPR35 (0.65) | GPR35MIFCA9MEN1GLA | |
| SCHEMBL3081130 | 0.73 | GPR35 (0.67) | GPR35MIFCA9MEN1GLA | |
| SCHEMBL3079094 | 0.73 | GPR35 (1.00) | GPR35MIFCA9MEN1GLA | |
| SCHEMBL15842472 | 0.72 | MIF (0.71) | GPR35MIFCA9MEN1GLA | |
| SCHEMBL28664040 | 0.71 | MAOB (0.66) | MIFMEN1GLAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989202-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2012-07-25 | — | — | EP | disclosed |
| US-8153797-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-7994323-B2 | Chromen-2-one derivatives | NEUROSEARCH A/S (DK) | 2011-08-09 | — | — | US | disclosed |
| EP-2158200-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH AS (DK) | 2011-07-13 | — | — | EP | disclosed |
| EP-2311835-A1 | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch AS (DK) | 2011-04-20 | — | — | EP | disclosed |
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100217002-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| EP-2158200-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NeuroSearch A/S (DK) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008138854-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2008-11-20 | — | — | WO | disclosed |
| EP-1989202-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007093604-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC6A2, SLC18A2, SLC18A1 | GPR35 1214/4885MIF 1514/4885CA9 4370/4885 |
| US-20100217002-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | CBX2, CYP2J2, CDYL2 | GPR35 3966/4885MIF 1998/4885CA9 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.